Filter Size Not the Anticoagulation Method is the Decisive Factor in Continuous Renal Replacement Therapy Circuit Survival

被引:16
作者
Miklaszewska, Monika [1 ]
Korohoda, Przemyslaw [2 ]
Zachwieja, Katarzyna [1 ]
Kobylarz, Krzysztof [3 ]
Stefanidis, Constantinos J. [4 ]
Sobczak, Alina [5 ]
Drozdz, Dorota [1 ]
机构
[1] Jagiellonian Univ, Coll Med, Dept Pediat Nephrol & Hypertens, Wielicka St 265, PL-30663 Krakow, Poland
[2] AGH Univ Sci & Technol, Fac Comp Sci Elect & Telecommun, Dept Elect, Krakow, Poland
[3] Jagiellonian Univ, Coll Med, Inst Pediat, Dept Anesthesiol & Intens Care, Krakow, Poland
[4] A&P Kyriakou Childrens Hosp, Dept Pediat Nephrol, Athens, Greece
[5] Jagiellonian Univ, Fac Med, Dept Pediat, Krakow, Poland
关键词
CRRT; PICU; Anticoagulation; Circuit; Filter; Clotting; REGIONAL CITRATE ANTICOAGULATION; RANDOMIZED CONTROLLED-TRIALS; CRITICALLY-ILL PATIENTS; HEPARIN ANTICOAGULATION; CRITICAL-CARE; METAANALYSIS; CHILDREN; PATENCY; UPDATE;
D O I
10.1159/000477609
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Background/Aim: As continuous renal replacement therapy (CRRT) has emerged as a standard therapy in pediatric intensive care units (PICU), many related issues that may have an impact on circuit survival have gained in importance. Objective of the study was an evaluation of factors associated with circuit survival, including anticoagulation (ACG). Methods: Retrospective study that included 40 patients, who in total received 7636 hours of CRRT during 150 sessions (84 filters, 4260 hours with heparin anticoagulation (Hep-ACG); 66 filters, 3376 hours with regional citrate anticoagulation (RCA)). Results: The Kaplan-Meier analysis of the total circuit survival time depending on the type of ACG did not demonstrate a significant difference between Hep-ACG and RCA. The percentage of clotted filters was significantly higher in case of smaller filters (HF20: 58.8%; ST60:29.5%; ST100: 15.8%), and their lifetime was significantly lower regardless of ACG (the mean and median lifetime for HF2O: 38.7/27.0 h; for ST60: 54.1/72.0 h., for ST100: 62.1/72.0 h, respectively). Conclusions: Irrespectively of filter size, filter clotting occurs within the first 24 hours after the initiation of CRRT. Most commonly, clotting affects small filters, and their lifetime is significantly shorter as compared to larger filters regardless of the type of the ACG. (C) 2017 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:327 / 337
页数:11
相关论文
共 24 条
[11]   Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution [J].
Morabito, Santo ;
Pistolesi, Valentina ;
Tritapepe, Luigi ;
Zeppilli, Laura ;
Polistena, Francesca ;
Strampelli, Emanuela ;
Pierucci, Alessandro .
CRITICAL CARE, 2012, 16 (03)
[12]   Citrate Anticoagulation for CRRT in Children: Comparison with Heparin [J].
Nicole Fernandez, Sara ;
Jose Santiago, Maria ;
Lopez-Herce, Jesus ;
Garcia, Miriam ;
Del Castillo, Jimena ;
Jose Alcaraz, Andres ;
Maria Bellon, Jose .
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[13]   Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate? [J].
Oudemans-van Straaten, Heleen M. ;
Kellum, John A. ;
Bellomo, Rinaldo .
CRITICAL CARE, 2011, 15 (01)
[14]  
Rico MP, 2017, PEDIATR NEPHROL, V32, P703, DOI 10.1007/s00467-016-3544-9
[15]   Advances in Pediatric Renal Replacement Therapy [J].
Sebestyen, Judith F. ;
Warady, Bradley A. .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2011, 18 (05) :376-383
[16]   Citrate anticoagulation for continuous renal replacement therapy in small children [J].
Soltysiak, Jolanta ;
Warzywoda, Alfred ;
Kocinski, Bartomiej ;
Ostalska-Nowicka, Danuta ;
Benedyk, Anna ;
Silska-Dittmar, Magdalena ;
Zachwieja, Jacek .
PEDIATRIC NEPHROLOGY, 2014, 29 (03) :469-475
[17]   Advances in Continuous Renal Replacement Therapy: Citrate Anticoagulation Update [J].
Tolwani, Ashita ;
Wille, Keith M. .
BLOOD PURIFICATION, 2012, 34 (02) :88-93
[18]   A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance [J].
Tolwani, Ashita J. ;
Prendergast, Mary B. ;
Speer, Rajesh R. ;
Stofan, Brenda S. ;
Wille, Keith M. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (01) :79-87
[19]  
Vinsonneau C, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0093-5
[20]   Dialysis therapy for children with acute renal failure: survey results [J].
Warady, BA ;
Bunchman, T .
PEDIATRIC NEPHROLOGY, 2000, 15 (1-2) :11-13